Navigation Links
ACP issues recommendations for management of high blood glucose in hospitalized patients
Date:5/23/2013

PHILADELPHIA, May 24, 2013 -- High blood glucose is associated with poor outcomes in hospitalized patients, and use of intensive insulin therapy (IIT) to control hyperglycemia is a common practice in hospitals. But the recent evidence does not show a consistent benefit and even shows harms associated with the use of IIT, according to the American College of Physicians' (ACP) Clinical Guidelines Committee in a new evidence-based paper published today online in the American Journal of Medical Quality.

"Clinicians caring for hospitalized patients must keep the harms of hypoglycemia in mind when managing hyperglycemia and should avoid aggressive glucose management," said Amir Qaseem, MD, PhD, MHA, FACP, Director, Clinical Policy, ACP. "Intensive insulin therapy should not be used to strictly control blood glucose or to normalize blood glucose in SICU and MICU patients with or without diabetes."

ACP recommends that clinicians should target a blood glucose level of 140 to 200 mg/dL if IIT is used in surgical or medical intensive care unit patients (SICU/MICU) and clinicians should avoid targets less than 140 mg/dL because harms are likely to increase with lower blood glucose targets.

Evidence for Benefits, Harms, and Costs of IIT

ACP's review of the evidence found that IIT with a goal of achieving normal or near-normal blood glucose in patients with or without diabetes does not provide substantial benefits and may lead to harm. The results from various studies indicate that using IIT to achieve strict glucose control compared to standard therapy with less strict control did not reduce mortality or length of hospital stay but did substantially increase the risk for severe hypoglycemia, especially in critically ill patients.

"The current evidence does not support that the benefits of intensive insulin therapy outweigh its harms," said Dr. Qaseem. "In addition, intensive insulin therapy consumes more resources and is a more expensive than managing hyperglycemia with standard therapy."

IIT costs include implementation in a hospital and downstream expenses incurred to manage the consequent harms. No recent cost-effectiveness studies have incorporated results from the recent trials to evaluate the impact of IIT in light of the new evidence.

ACP's High Value Care Initiative

"Inpatient Glycemic Control" is part of ACP's High Value Care initiative, launched in 2010 to help physicians provide the best possible care to their patients while simultaneously reducing unnecessary health care costs. ACP defines high value care as the delivery of services providing benefits that make their harms and costs worthwhile.

Value is not merely cost. Some expensive tests and treatments have high value because they provide high benefit and low harm. Conversely, some inexpensive tests or treatments have low value because they do not provide enough benefit to justify even their low costs and might even be harmful.

ACP's evidence-based recommendations aim to educate physicians and patients about how to pursue care together that improves health, avoids harms, and eliminates wasteful practices.


'/>"/>

Contact: Steve Majewski
smajewski@acponline.org
American College of Physicians
Source:Eurekalert

Related medicine news :

1. UCSF chancellor issues call-to-arms to patient advocates
2. Radiologists rank themselves as less than competent on health policy issues
3. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
4. FDA Issues Multiple Sclerosis Drug Alert
5. Quality of care, other issues may cause worse results in black prostate cancer surgery patients
6. U.S. Task Force Issues Blood Pressure Guidelines
7. Internists in Washington to discuss patient and professional issues in meetings on Capitol Hill
8. Cheaper drug could lead to serious eye issues
9. Insulite Labs announces the launch of the PCOS Inspiration Hour, a one hour virtual gathering place for women with PCOS and other women’s health issues to come together.
10. LawyersandSettlements.com Issues Report on Prostate Health Claim Lawsuits and Propecia Side Effect Litigation
11. What Men Should Know About Veins: Varicose Veins and Venous Disease are Real Medical Issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... Patient warming and ... blood during surgeries, lowering the risks of neurological disorders post ... SSIs. The patient warming systems can be segmented into convective ... in turn reduce the stay at hospitals thus, lowering the ...
Breaking Medicine Technology: